Drug Profile
SPC 2996
Alternative Names: LNA antisense molecule against Bcl-2 - Santaris; SPC-2996Latest Information Update: 02 Oct 2021
Price :
$50
*
At a glance
- Originator Santaris Pharma
- Class Antineoplastics; Oligonucleotides
- Mechanism of Action Proto-oncogene protein c-bcl-2 inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued Burkitt's lymphoma; Chronic lymphocytic leukaemia; Non-Hodgkin's lymphoma; Solid tumours
Most Recent Events
- 14 Jul 2009 Discontinued - Phase-I/II for Chronic lymphocytic leukaemia in Denmark (IV)
- 14 Jul 2009 Discontinued - Phase-I/II for Chronic lymphocytic leukaemia in France (IV)
- 14 Jul 2009 Discontinued - Phase-I/II for Chronic lymphocytic leukaemia in United Kingdom (IV)